Rifampicin-resistant tuberculosis in Iran: A systematic review and meta-analysis

被引：6

作者：

Bahraminia, Farhad ^{[1
]}

Azimi, Taher ^{[2
]}

Zangiabadian, Moein ^{[3
]}

Nasiri, Mohammad Javad ^{[4
]}

Goudarzi, Mehdi ^{[4
]}

Dadashi, Masoud ^{[5
]}

Fooladi, Abbas Ali Imani ^{[1
]}

机构：

[1] Baqiyatallah Univ Med Sci, Syst Biol & Poisonings Inst, Appl Microbiol Res Ctr, Tehran, Iran

[2] Univ Tehran Med Sci, Sch Publ Hlth, Dept Pathobiol, Tehran, Iran

[3] Shahid Beheshti Univ Med Sci, Sch Med, Student Res Comm, Tehran, Iran

[4] Shahid Beheshti Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran

[5] Alborz Univ Med Sci, Sch Med, Dept Microbiol, Karaj, Iran

来源：

IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES | 2021年 / 24卷 / 06期

关键词：

Drug resistance; Iran; Rifampicin; Tuberculosis; Xpert MTB; RIF assay;

D O I：

10.22038/ijbms.2021.47360.10901

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Rifampicin (RIF)-resistant strain of Mycobacterium tuberculosis is an important barrier to effective tuberculosis (TB) treatment and prevention. The present study aimed to determine the frequency of RIF-resistant TB among patients with confirmed TB. Pubmed/Medline, Embase, Web of Science, and Scopus were searched for relevant articles published between January 1980 and January 2020. We pooled data with random-effects models when appropriate. After screening 1608 citations, 30 studies covering 8215 patients with TB were included. The pooled frequency of RIF-resistance among all patients with TB was 8.0% (95% CI 4.0-12.0). Our sub-group analysis showed that 4.0% of newly diagnosed cases and 36.0% of previously-treated TB patients from different settings in Iran were RIFresistant. Our study showed that the frequency of RIF-resistance among patients with TB was 8.0%. Programmatic implementation of rapid drug susceptibility testing (DST) such as the Xpert MTB/RIF assay as a primary diagnostic test for persons suspected of having a RIF-resistant TB would be helpful for the control of the drug resistance.

引用

页码：720 / 725

页数：6

共 1 条

[1] Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial [J].

Theron, Grant ;

Zijenah, Lynn ;

Chanda, Duncan ;

Clowes, Petra ;

Rachow, Andrea ;

Lesosky, Maia ;

Bara, Wilbert ;

Mungofa, Stanley ;

Pai, Madhukar ;

Hoelscher, Michael ;

Dowdy, David ;

Pym, Alex ;

Mwaba, Peter ;

Mason, Peter ;

Peter, Jonny ;

Dheda, Keertan .

LANCET, 2014, 383 (9915) :424-435

← 1 →